Initiation of Sodium-Glucose Cotransporter 2 inhibitors after first hospitalization for heart failure: a population-based cohort study

First published: 20/03/2025

Last updated: 19/12/2025

Study Finalised

Administrative details

EU PAS number

EUPAS1000000378

Study ID

1000000378

DARWIN EU® study

No

Study countries

☐ France

Study description

This study aims to describe SGLT-2i initiation after discharge from first heart failure hospitalization in France between 2021 and 2023.

Study status

Finalised

Research institutions and networks

Institutions

Toulouse University Hospital

First published: 01/02/2024

Last updated: 01/02/2024

Institution

University Toulouse III

France

First published: 01/02/2024

Last updated: 01/02/2024

Institution | Educational Institution

Pharmacologie En Population cohorteS biobanqueS (PEPSS), Hopitaux de Toulouse

France

First published: 31/03/2022

Last updated: 01/07/2024

Institution | Educational Institution | Hospital/Clinic/Other health care facility | ENCePP partner

Contact details

Study institution contact

Maryse LAPEYRE-MESTRE maryse.lapeyre-mestre@univ-tlse3.fr

Study contact

maryse.lapeyre-mestre@univ-tlse3.fr

Primary lead investigator

Paul Gautier 0009-0008-9934-8432

Primary lead investigator

ORCID number:

0009-0008-9934-8432

Study timelines

Date when funding contract was signed

Planned: 01/11/2024

Actual: 01/11/2024

Study start date
Planned: 14/11/2024

Data analysis start date
Planned: 14/12/2024

Date of final study report
Planned: 01/02/2024

Actual: 01/06/2025

Sources of funding

- No external funding

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary use of data

Study design:

Cohort study of patients discharged from first hospitalization for heart failure between 2021 and 2023.

Main study objective:

Proportion of SGLT-2i initiation at 30 days after discharge.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

DAPAGLIFLOZIN VIATRIS

Medicinal product name, other

Empagliflozin

Study drug International non-proprietary name (INN) or common name

DAPAGLIFLOZIN

EMPAGLIFLOZIN

Anatomical Therapeutic Chemical (ATC) code

(A10BK) Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

(A10BK01) dapagliflozin

dapagliflozin

(A10BK03) empagliflozin

empagliflozin

Medical condition to be studied

Cardiac failure

Population studied

Short description of the study population

Patients > 18 years discharged from first hospitalization for heart failure between 2021 and 2023

Age groups

- **Adult and elderly population (≥18 years)**

Special population of interest

Renal impaired

Special population of interest, other

Diabetes

Estimated number of subjects

300000

Study design details

Comparators

Not applicable.

Outcomes

SGLT-2i initiation in the 30 days following hospital discharge.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Système National des Données de Santé (French national health system main database)

Data sources (types)

Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Not applicable